The distribution of FGFR3 mutations in bladder tumors of different stages

Fibroblast growth factor receptor 3 (FGFR3) could represent a promising biomarker for bladder cancer. Current study consisted of 95 subjects with bladder cancer (Transitional cells carcinoma TCC) and 50 subjects control group. Patient age ranged from 30 to 86 years while control subjects ages ranged from 30 to 50 years. Mutations of FGFR3 genes were analyzed in 101 patients with transitional cell bladder cancer included 61(67%) male and 40(44%) female. 43 of 101 patients have mutations. 15(35.7%) of mutations shown in FGFR3 exon 7 and 27(64.3%) were in exon 10. These mutations affected codons g.13509, g.13501 of exon 7 and codons g.16021, g.16025 of exon 10. FGFR3 mutations were observed in 13(%) Ta tumors, 10(%) T1, 8(%) T2 and 11(%) T3 of 42 mutations. The occurrence of FGFR3 mutations with respect to tumor stage revealed the presence of a FGFR3 mutation in low stage tumors than high-stage tumors. These results indicate that a significant correlation was found between FGFR3 mutations and low grade.